Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Down 28.9% in February

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) saw a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 29,500 shares, a decline of 28.9% from the February 13th total of 41,500 shares. Approximately 2.4% of the company’s shares are sold short. Based on an average daily volume of 56,600 shares, the days-to-cover ratio is currently 0.5 days.

Institutional Trading of Cadrenal Therapeutics

A hedge fund recently bought a new stake in Cadrenal Therapeutics stock. Geode Capital Management LLC acquired a new stake in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 10,554 shares of the company’s stock, valued at approximately $153,000. Geode Capital Management LLC owned 0.59% of Cadrenal Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 7.92% of the company’s stock.

Cadrenal Therapeutics Stock Up 1.1 %

Shares of Cadrenal Therapeutics stock traded up $0.22 during mid-day trading on Tuesday, hitting $20.09. The stock had a trading volume of 20,786 shares, compared to its average volume of 38,894. The firm has a 50-day moving average of $18.38 and a two-hundred day moving average of $15.23. The firm has a market cap of $35.82 million, a P/E ratio of -3.00 and a beta of 1.40. Cadrenal Therapeutics has a 12-month low of $5.40 and a 12-month high of $22.90.

Cadrenal Therapeutics (NASDAQ:CVKD) last announced its earnings results on Thursday, March 13th. The company reported ($2.74) earnings per share for the quarter, missing the consensus estimate of ($1.71) by ($1.03). Sell-side analysts expect that Cadrenal Therapeutics will post -7.59 earnings per share for the current year.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.